Accessibility Menu
Hemogenyx Pharmaceuticals Plc logo

Hemogenyx Pharmaceuticals Plc(LSE) HEMO

Market Cap£42.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-49%
5 Year-15%
1 Year+284%
1 Month-19%
£6.36
+2.91%
+0.18Today
Hemogenyx Pharmaceuticals Plc last closing stock price
MetricPriceDate
Last closeGBX 619.462026-08-20
Hemogenyx Pharmaceuticals Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.09%GBX 620.002026-08-13
1 month-19.08%GBX 765.502026-07-21
3 month-10.22%GBX 690.002026-05-22
Year to date+8.3%GBX 572.002025-12-31
1 year+284.16%GBX 161.252025-08-20
3 year-3.21%GBX 640.002023-08-21
5 year-15.14%GBX 730.002021-08-20
Since inception-48.5%GBX 12.002017-10-06

Hemogenyx Pharmaceuticals Plc Financials at a Glance

Market Cap

£42.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

£0.00

Net Income (TTM)

-£12.57M

EPS (TTM)

-£2.20

P/E Ratio

-2.81

Dividend

£0.00

Beta (Volatility)

0.06 (Low)

Price

£6.36

Volume

14,576

Open

£6.18

Previous Close

£6.36

Daily Range

£6.01 - £6.36

52-Week Range

£1.61 - £18.00

Estimated Earnings Date

Apr 27, 2026

HEMO News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Hemogenyx Pharmaceuticals Plc

Hemogenyx Pharmaceuticals Plc is a preclinical biotechnology company focused on developing innovative therapies for blood diseases. The company aims to advance treatments in the bone marrow and hematopoietic stem cell transplant sector, targeting conditions like acute myeloid leukaemia.

Products and Services
  • CDX bi-specific antibody for relapsed/refractory acute myeloid leukaemia
  • HEMO-CAR-T therapy utilizing chimeric antigen receptor T-cells
  • Human Postnatal Hematopoietic Endothelial Cells for transplant procedures
Growth Outlook
  • Strong focus on innovative therapies positions the company for future growth
  • Pipeline includes treatments for high unmet medical needs in oncology
  • Potential for partnerships with larger pharmaceutical companies
Financial Highlights
  • Recent quarterly net income of -£4.76 million, reflecting ongoing R&D investments
  • Cash and cash equivalents of £1.59 million as of Q4 2025
  • Trailing twelve months (TTM) P/E ratio of -2.90 indicates potential for future profitability
Hemogenyx Pharmaceuticals Plc is dedicated to addressing significant challenges in the treatment of blood diseases. The company's innovative pipeline, including therapies targeting acute myeloid leukaemia, showcases its commitment to advancing medical science. Despite recent financial losses, the focus on research and development may lead to future growth opportunities. The current cash position provides a foundation for ongoing projects, while the negative P/E ratio suggests that the market may be undervaluing the potential of these groundbreaking therapies. Investors may find interest in the company's strategic direction and its potential to make a meaningful impact in the biotechnology sector.
AI Generated • Aug 18, 2026

Industry

Biotechnology

Sector

Health Care

Employees

9

CEO

Vladislav Sandler, PhD

Website

hemogenyx.com

Headquarters

London, GL W1B 4BT, GB

HEMO Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-2807.75%

Return on Capital

-145.67%

Return on Assets

-233.73%

Earnings Yield

-35.59%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

£42.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

6.80M

Volume

14.58K

Avg. Volume

12.65K

Financials (TTM)

Gross Profit

-£1.55M

Operating Income

-£7.35M

EBITDA

-£13.45M

Operating Cash Flow

-£5.23M

Capital Expenditure

-£17.21K

Free Cash Flow

-£5.25M

Cash & ST Invst.

£1.59M

Total Debt

£2.00M

Hemogenyx Pharmaceuticals Plc Performance Analysis

Hemogenyx Pharmaceuticals Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31GBP 0N/A
20232023-12-31GBP 0N/A
20242024-12-31GBP 0N/A
20252025-12-31GBP 0N/A
Hemogenyx Pharmaceuticals Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30N/A
Q42024-12-31N/A
Q22025-06-30N/A
Q42025-12-31N/A
Hemogenyx Pharmaceuticals Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31GBP -2.06-22.0%
20232023-12-31GBP -2.3715.4%
20242024-12-31GBP -1.70-28.2%
20252025-12-31GBP -2.2029.1%
Hemogenyx Pharmaceuticals Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-3099.9%
Q42024-12-31-88788.9%
Q22025-06-30-77.5%
Q42025-12-3144.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

£0.00

N/A

Gross Profit

-£274.97K

+15.6%

Gross Margin

0.00%

N/A

Market Cap

£42.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

£2.63M

N/A

Employees

16

N/A

Net Income

-£4.76M

-100.7%

EBITDA

-£1.81M

+4.5%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

£1.59M

+27.2%

Total Debt

£2.00M

-32.0%

Accounts Receivable

£8.78K

+70.8%

Inventory

£0.00

N/A

Long Term Debt

£1.56M

-41.6%

Short Term Debt

£442.42K

-19.0%

Return on Assets

-2.34%

N/A

Return on Invested Capital

-1.72%

N/A

Free Cash Flow

£336.34K

+111.7%

Operating Cash Flow

£336.34K

+112.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SAR.LSareum Holdings plc
£0.28+0.00%
HVO.LhVIVO plc
£0.07+0.00%
KOO.LKooth plc
£1.48+0.00%
SBTX.LSkinBioTherapeutics Plc
£0.10+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
BITOProShares Trust - ProShares Bitcoin ETF
$9.81+0.06%
SPCXSpace Exploration Technologies
$134.00-0.04%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.88-0.03%
IBITiShares Bitcoin Trust
$41.20+0.06%

Questions About HEMO

What is the current price of Hemogenyx Pharmaceuticals Plc?

Hemogenyx Pharmaceuticals Plc is trading at £6.36 per share.

What is the 52-week range for Hemogenyx Pharmaceuticals Plc?

Over the past 52 weeks, Hemogenyx Pharmaceuticals Plc has traded between £1.61 and £18.00.

How much debt does Hemogenyx Pharmaceuticals Plc have?

As of the most recent reporting period, Hemogenyx Pharmaceuticals Plc reported total debt of £2.00M.

How much cash does Hemogenyx Pharmaceuticals Plc have on hand?

Hemogenyx Pharmaceuticals Plc reported £1.59M in cash and cash equivalents in its most recent financial results.

What is Hemogenyx Pharmaceuticals Plc’s dividend yield?

Hemogenyx Pharmaceuticals Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services